Malaria

Study shows Corixa's MPL adjuvant protected against uncomplicated malaria

Published in Medical Letter on the CDC and FDA, November 21st, 2004

In a proof-of-concept study to be published in the The Lancet, researchers report that GlaxoSmithKline (GSK) Biologicals' RTS,S/AS02A malaria vaccine candidate containing Corixa's (Nasdaq:CRXA) MPL adjuvant protected a significant percentage of children against uncomplicated malaria, infection, and even severe forms of the disease for at least 6 months.

This largest malaria vaccine efficacy trial ever conducted in Africa also reconfirmed the vaccine's safety in one-to-4 year old children. Further efficacy studies will be needed before consideration for licensure.

The double-blind, controlled trial involved 2,022 children in southern Mozambique...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2004-11-21)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry